Press Releases
Dailies Total1 Multifocal contact lenses launched for presbyopia- Alcon
Alcon, the global leader in eye care and a division of Novartis, introduces Dailies Total1 Multifocal contact lenses for people with presbyopia. This innovative multifocal lens provides both seamless distant, intermediate and near vision, and the outstanding comfort of...
Press Releases
Boehringer Ingelheim and University of Dundee collaborate to develop new class of medicines
Collaboration aims to develop PROteolysis TArgeting Chimeric molecules (PROTACs) – a new therapeutic modality that is able to degrade proteins playing a central role in disease processes PROTACs and their new mechanism of action are expected to open...
Press Releases
Health Canada approves Abbott’s Absorb Bioresorbable Stent
Revolutionary Device Made Of Naturally Dissolving Material, Similar To Dissolving Sutures Treats Coronary Artery Disease Like A Metallic Stent, But Then Disappears After The Artery Is Healed, Leaving No Metal Behind To Restrict Natural Vessel Motion....
Press Releases
Sandoz Biosimilar Etanercept Recommended By US FDA For Approval To Treat Multiple Inflammatory Diseases
Sandoz, a Novartis division and leader in biosimilars, announced that the US FDA Advisory Committee recommended approval of its proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference...
Press Releases
U.S. FDA Grants Priority Review to Janssen’s New Drug Application for Chewable Mebendazole Tablets
Janssen Pharmaceuticals, Inc announced that the U.S. FDA has granted Priority Review designation for the NDA for a 500mg chewable tablet formulation of mebendazole. Â If approved, the chewable mebendazole tablet will provide a treatment and prevention alternative for adults...
Press Releases
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan
Amgen and Daiichi Sankyo Company, Limited announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab. Under the...
Press Releases
AbbVie Receives U.S. FDA Rare Pediatric Disease Designation for Investigational ABT-414
AbbVie a global biopharmaceutical company, announced that the U.S. FDA granted Rare Pediatric Disease Designation for ABT-414, an investigational antibody drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), for the treatment of pediatric patients with EGFR-amplified Diffuse...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read